Consensus guideline for the diagnosis and treatment of aromatic l-amino acid decarboxylase (AADC) deficiency
- PMID: 28100251
- PMCID: PMC5241937
- DOI: 10.1186/s13023-016-0522-z
Consensus guideline for the diagnosis and treatment of aromatic l-amino acid decarboxylase (AADC) deficiency
Abstract
Aromatic L-amino acid decarboxylase deficiency (AADCD) is a rare, autosomal recessive neurometabolic disorder that leads to a severe combined deficiency of serotonin, dopamine, norepinephrine and epinephrine. Onset is early in life, and key clinical symptoms are hypotonia, movement disorders (oculogyric crisis, dystonia, and hypokinesia), developmental delay, and autonomic symptoms.In this consensus guideline, representatives of the International Working Group on Neurotransmitter Related Disorders (iNTD) and patient representatives evaluated all available evidence for diagnosis and treatment of AADCD and made recommendations using SIGN and GRADE methodology. In the face of limited definitive evidence, we constructed practical recommendations on clinical diagnosis, laboratory diagnosis, imaging and electroencephalograpy, medical treatments and non-medical treatments. Furthermore, we identified topics for further research. We believe this guideline will improve the care for AADCD patients around the world whilst promoting general awareness of this rare disease.
Der Aromatische L-Aminosäuren Decarboxylase Mangel (AADCD) ist eine seltene autosomal rezessive neurometabolische Störung, die zu einem schweren kombinierten Mangel an Serotonin, Dopamin, Norepinephrin und Epinephrin führt. Die Symptome setzen in einer frühen Phase des Lebens ein. Die klinischen Hauptsymptome sind muskuläre Hypotonie, Bewegungsstörungen (Okkulogyre Krisen, Dystonie und Hypokinesie), Entwicklungsverzögerung und autonome Symptome.
In diesen Konsensus basierten Leitlinien haben Mitglieder der “International Working Group on Neurotransmitter Related Disorders (iNTD)” sowie Patientenvertreter die verfügbare Evidenz für die Diagnose und Behandlung von AADCD ausgewertet und evidenzbasierte Empfehlungen nach den Methoden von SIGN und GRADE formuliert. Stets im Bewusstsein der limitierten Evidenz haben wir praktische Empfehlungen für die klinische Diagnose, Labordiagnose, Bildgebung und EEG, medizinische und nicht medizinische Behandlung formuliert. Des Weiteren haben wir Themen identifiziert, die der weiteren Forschung bedürfen. Wir glauben, dass diese Leitlinie die Behandlung von Patienten mit AADCD verbessert und gleichzeitig das Bewusstsein für diese seltene Erkrankung geschärft wird.
Electronic supplementary material: The online version of this article (doi:10.1186/s13023-016-0522-z) contains supplementary material, which is available to authorized users.
La deficiencia de la descarboxilasa de aminoácidos aromáticos (AADCD) es una enfermedad neurometabólica minoritaria de herencia autosómica recesiva que causa un defecto grave de dopamina, serotonina, epinefrina y norepinefrina. El inicio de la enfermedad es precoz, y sus síntomas principales incluyen hipotonía, trastornos del movimiento (crisis oculógiras, distonía e hipocinesia), retraso del desarrollo y signos disautonómicos.
En esta guía de consenso han participado representantes del grupo de trabajo internacional sobre trastornos de la neurotransmisión (iNTD) y representantes de las asociaciones de pacientes, que han evaluado todas las evidencias existentes en relación al diagnóstico y tratamiento de la AADCD. Las recomnedaciones se han realizado siguiendo la metodología SIGN y GRADE. A pesar de los bajos niveles de evidencia existentes, se han podido establecer recomendaciones prácticas y que pueden ser muy útiles sobre el diagnóstico clínico y de laboratorio, las pruebas de neuroimagen y electroencefalográficas y sobre tratamientos tanto médicos como de soporte. Se han identificado además temas que pueden ser interesantes a desarrollar en el campo de la investigación de la AADCD.
En conclusión, pensamos que esta guía aumentará la calidad en los cuidados de los pacientes con AADCD en todo el mundo, y que aumentará el conocimiento de esta rara enfermedad.
Electronic supplementary material: The online version of this article (doi:10.1186/s13023-016-0522-z) contains supplementary material, which is available to authorized users.
Keywords: AADC deficiency; Aromatic l-amino acid decarboxylase deficiency; Dopamine; GRADE; Guideline; Infantile dystonia-parkinsonism; Neurotransmitter; SIGN; Serotonin.
Figures
![Fig. 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5241937/bin/13023_2016_522_Fig1_HTML.gif)
![Fig. 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5241937/bin/13023_2016_522_Fig2_HTML.gif)
Similar articles
-
Aromatic amino acid decarboxylase deficiency: Molecular and metabolic basis and therapeutic outlook.Mol Genet Metab. 2019 May;127(1):12-22. doi: 10.1016/j.ymgme.2019.03.009. Epub 2019 Mar 27. Mol Genet Metab. 2019. PMID: 30952622 Review.
-
Aromatic L-amino acid decarboxylase deficiency: clinical features, treatment, and prognosis.Neurology. 2004 Apr 13;62(7):1058-65. doi: 10.1212/wnl.62.7.1058. Neurology. 2004. PMID: 15079002 Review.
-
Aromatic L-amino acid decarboxylase deficiency in Taiwan.Eur J Paediatr Neurol. 2009 Mar;13(2):135-40. doi: 10.1016/j.ejpn.2008.03.008. Epub 2008 Jun 24. Eur J Paediatr Neurol. 2009. PMID: 18567514
-
AADC deficiency from infancy to adulthood: Symptoms and developmental outcome in an international cohort of 63 patients.J Inherit Metab Dis. 2020 Sep;43(5):1121-1130. doi: 10.1002/jimd.12247. Epub 2020 May 14. J Inherit Metab Dis. 2020. PMID: 32369189 Free PMC article.
-
Aromatic L-amino acid decarboxylase deficiency: clinical features, drug therapy and follow-up.J Inherit Metab Dis. 2009 Jun;32(3):371-80. doi: 10.1007/s10545-009-1076-1. Epub 2009 Jan 28. J Inherit Metab Dis. 2009. PMID: 19172410
Cited by
-
Adeno-associated virus as a delivery vector for gene therapy of human diseases.Signal Transduct Target Ther. 2024 Apr 3;9(1):78. doi: 10.1038/s41392-024-01780-w. Signal Transduct Target Ther. 2024. PMID: 38565561 Free PMC article. Review.
-
An attenuated, adult case of AADC deficiency demonstrated by protein characterization.Mol Genet Metab Rep. 2024 Mar 16;39:101071. doi: 10.1016/j.ymgmr.2024.101071. eCollection 2024 Jun. Mol Genet Metab Rep. 2024. PMID: 38524666 Free PMC article.
-
Aromatic L-Amino Acid Decarboxylase Deficiency: A Genetic Screening in Sicilian Patients with Neurological Disorders.Genes (Basel). 2024 Jan 21;15(1):134. doi: 10.3390/genes15010134. Genes (Basel). 2024. PMID: 38275615 Free PMC article.
-
A position statement on the post gene-therapy rehabilitation of aromatic I-amino acid decarboxylase deficiency patients.Orphanet J Rare Dis. 2024 Jan 18;19(1):17. doi: 10.1186/s13023-024-03019-x. Orphanet J Rare Dis. 2024. PMID: 38238766 Free PMC article.
-
Genetic Testing of Movements Disorders: A Review of Clinical Utility.Tremor Other Hyperkinet Mov (N Y). 2024 Jan 8;14:2. doi: 10.5334/tohm.835. eCollection 2024. Tremor Other Hyperkinet Mov (N Y). 2024. PMID: 38222898 Free PMC article. Review.
References
-
- Leuzzi V, Mastrangelo M, Polizzi A, Artiola C, van Kuilenburg AB, Carducci C et al. Report of two never treated adult sisters with aromatic L-amino acid decarboxylase deficiency: a portrait of the natural history of the disease or an expanding phenotype? JIMD Rep. 2014. doi:10.1007/8904_2014_295. - PMC - PubMed
Publication types
MeSH terms
Substances
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical